Abstract:AbstractThe transcription factor NRF2 (NFE2L2) is a pivotal activator of genes encoding cytoprotective and detoxifying enzymes that limit the action of cytotoxic therapies in cancer. NRF2 acts by binding antioxidant response elements (ARE) in its target genes, but there is relatively limited knowledge about how it is negatively controlled. Here, we report that retinoic X receptor alpha (RXRα) is a hitherto unrecognized repressor of NRF2. RNAi-mediated knockdown of RXRα increased basal ARE-driven gene expression and induction of ARE-driven genes by the NRF2 activator tert-butylhydroquinone (tBHQ). Conversely, overexpression of RXRα decreased ARE-driven gene expression. Biochemical investigations showed that RXRα interacts physically with NRF2 in cancer cells and in murine small intestine and liver tissues. Furthermore, RXRα bound to ARE sequences in the promoters of NRF2-regulated genes. RXRα loading onto AREs was concomitant with the presence of NRF2, supporting the hypothesis that a direct interaction between the two proteins on gene promoters accounts for the antagonism of ARE-driven gene expression. Mutation analyses revealed that interaction between the two transcription factors involves the DNA-binding domain of RXRα and a region comprising amino acids 209-316 in human NRF2 that had not been defined functionally, but that we now designate as the NRF2-ECH homology (Neh) 7 domain. In non–small cell lung cancer cells where NRF2 levels are elevated, RXRα expression downregulated NRF2 and sensitized cells to the cytotoxic effects of therapeutic drugs. In summary, our findings show that RXRα diminishes cytoprotection by NRF2 by binding directly to the newly defined Neh7 domain in NRF2. Cancer Res; 73(10); 3097–108. ©2013 AACR.

The Short Isoform of PML‐RARα Activates the NRF2/HO‐1 Pathway Through a Direct Interaction with NRF2

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Supplementary Figure 5 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 6 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 4 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 1 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 3 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 7 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Pml/Rar Alpha Fusion Protein Transactivates The Tissue Factor Promoter Through A Gagc-Containing Element Without Direct Dna Association

Supplementary Methods from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 2 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Identification of Retinoic Acid As an Inhibitor of Transcription Factor Nrf2 Through Activation of Retinoic Acid Receptor Alpha

Dimerization-Induced Corepressor Binding and Relaxed Dna-Binding Specificity Are Critical for Pml/Rara-Induced Immortalization

Effect of PML-RARα on transcriptional regulation by Smad

Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor Alpha (raralpha) and Oncogenic RARalpha Fusion Proteins.

Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor Α (RAR Α ) and Oncogenic RAR Α Fusion Proteins

PML/RARα Targets Promoter Regions Containing PU.1 Consensus and RARE Half Sites in Acute Promyelocytic Leukemia

PML‐RARα Interferes with Erythropoiesis by Repressing LMO2 in Acute Promyelocytic Leukaemia

A PML/RARα Direct Target Atlas Redefines Transcriptional Deregulation in Acute Promyelocytic Leukemia

Transcriptional inhibition of GADD45A by PML/RARα

Pml/Rar Alpha Targets Promoter Regions Containing Pu.1 Consensus And Rare Half Sites In Acute Promyelocytic Leukemia